Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer

This project plans to use CIK combined with chemotherapy, immunotherapy and targeted therapy to treat CRC patients, so as to explore the effectiveness of CIK treatment and the CRC subtypes more suitable for CIK treatment, thereby improving the survival rate and quality of life of CRC patients.

Trial Details

NCT ID
NCT05676190
Phase
NA
Sponsor
ShiCang Yu
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • CIK combined with chemotherapy group
  • CIK combined immunotherapy group
  • CIK combined targeted therapy group
  • CIK in combination with other therapies
Locations (sample)
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

  • Age range 18-70 years;
  • Patients diagnosed with colorectal cancer, TNM stage III-IV;
  • Had at least one extracranially measurable lesion by recist1.1 criteria; ④ Patients who had failed at least one or two prior lines of standard ther…
  • The major organs function normally; ⑦ The subject voluntarily joined this study, signed the informed consent, complied well and cooperated with the…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →